Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought 3,057 shares of Common Stock in an open-market purchase at $1.93 per share on July 1, 2026. After this trade, he directly owns 15,492 shares, plus additional indirect holdings through related entities.

Insider Trade Summary

Net Buyer: 3,057 shares ($5,900)

Net Buy 3 txns

Insider Ng George K

Role Chief Executive Officer

Bought 3,057 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	3,057	$1.93	$6K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 15,492 shares (Direct, null); Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng)

Footnotes (1)

Key Figures

Shares purchased: 3,057 shares Purchase price: $1.93 per share Direct holdings after trade: 15,492 shares +2 more

5 metrics

Shares purchased 3,057 shares Open-market buy on July 1, 2026

Purchase price $1.93 per share Open-market transaction code P

Direct holdings after trade 15,492 shares Common Stock directly owned by CEO

Indirect trust holdings 800 shares Ng Cha Family Trust

Other indirect holdings 3,488 shares George Ng IRRA FOB George Ng

Key Terms

open-market purchase, indirect holdings, Common Stock, Form 4

4 terms

open-market purchase financial

"bought 3,057 shares of Common Stock in an open-market purchase at"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect holdings financial

"plus additional indirect holdings through related entities"

Common Stock financial

"bought 3,057 shares of Common Stock in an open-market purchase"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"What insider transaction did PCSA CEO George Ng report on this Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:19 PM Accepted by SEC EDGAR 07/01/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		P		3,057	A	$1.93	15,492	D
Common Stock								3,488	I	George Ng IRRA FOB George Ng
Common Stock								800	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA CEO George Ng report on this Form 4?

George K. Ng, CEO of Processa Pharmaceuticals (PCSA), reported buying 3,057 shares of Common Stock in an open-market transaction at $1.93 per share on July 1, 2026, increasing his directly held stake in the company.

How many Processa Pharmaceuticals (PCSA) shares does the CEO hold after this trade?

After the reported transaction, CEO George K. Ng directly holds 15,492 shares of Processa Pharmaceuticals Common Stock. The filing also lists additional indirect holdings through the Ng Cha Family Trust and an account labeled “George Ng IRRA FOB George Ng.”

Was the PCSA CEO’s recent share transaction a purchase or a sale?

The Form 4 shows a purchase. CEO George K. Ng executed an open-market buy of 3,057 Processa Pharmaceuticals Common Stock shares at $1.93 per share, classified under transaction code P for purchase, with no reported share sales in this filing.

What indirect PCSA share holdings related to the CEO are disclosed?

The filing lists 800 shares held indirectly through the Ng Cha Family Trust and 3,488 shares held indirectly via an account titled “George Ng IRRA FOB George Ng.” These are reported as indirect ownership interests separate from his direct 15,492-share holding.

Does this PCSA Form 4 report any derivative securities for the CEO?

The disclosed data show no derivative securities reported for CEO George K. Ng in this Form 4. The derivativeSummary section is empty, indicating no listed options, warrants, or other derivative positions associated with this specific filing snapshot.